Weight-related conditions that may support eligibility include hypertension, prediabetes, type 2 diabetes, high cholesterol, obstructive sleep apnea, and cardiovascular disease
Three medications represent this progression: Semaglutide (single agonist, 15% average weight loss), Tirzepatide (dual agonist, 22.5% weight loss), and Retatrutide (triple agonist, 28.7% weight loss)
Retatrutide hits the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor
People Who Switched to Orforglipron Kept the Weight Off The trial included nearly 400 adults who were overweight or had obesity and who had already completed another large trial, SURMOUNT-5
The phase 2 trial tested different starting dose strategies and found that slower titration reduced side effects but also delayed the onset of maximum weight loss
Then I started using the HIMIYER GLP-1 SIX IN-ONE Health Solution Oral Liquid